French drugmaker Sanofi has initiated process to demerge its Indian consumer business and turn it into a listed entity, The Economic Times reported. Sanofi and subsidiary Hoechst GmbH hold about 60% stake in Sanofi India and the consumer business will reportedly be listed separately with a similar shareholding pattern. The consumer business reportedly posted revenue of ₹1,000-1,250 crore in 2022.